Risk factors of metabolic estrogen-deficiency syndrom and its relationship to hormone replacement therapy;Rizikové faktory metabolického estrogen-deficitního syndromu u žen po menopauze a jejich vztah k hormonální substituční terapii

Ceska Gynekologie

Volumn 69, Issue 5, 2004, Pages 388-396

  Šormová, Irena ^a   Donat J ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Cardiovascular risk factors; Hormone replacement therapy; Menopause; Osteoporosis

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HOMOCYSTEINE; LIPID;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE MEASUREMENT; BODY MASS; BONE DENSITY; BONE MINERAL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CULTURAL FACTOR; DIASTOLIC BLOOD PRESSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN DEFICIENCY; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HIP DISEASE; HORMONE SUBSTITUTION; HUMAN; LIPID ANALYSIS; LONG TERM CARE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEMORY DISORDER; OSTEOPOROSIS; POSTMENOPAUSE; SOCIAL LIFE;

AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RISK FACTORS;

EID: 7644235848     PISSN: 12107832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Bafour, IL, Basak, Y., Suleyman, D., Erkan, A.: Effect of love-dose 17β-estradiol plus norethisterone acetate and tibolone on fasting plasma homocysteine levels in postmenopausal women. Acta Obstet. Gynec. Scand., 2003, vol. 82, p. 1107-1114.
2. Blumenthal, R. S., Post, W. S.: HERS revisited: Is postmenopausal hormone replacement therapy cardioprotective? Menopause Management, 1999, vol. 8, 4, p. 15-20.
3. Crook, D., Cust, M. P., Ganger, K. F., et al.: Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effect on serum lipids and lipoproteins. Am. J. Obstet. Gynecol., 1992, vol. 166, p. 950-955.
4. Douát, J.: Diskuse nad estrogeny - kdo podvádí ženy? Klimakter. Med., 2002, vol. 7, č. 3, s. 7-9.
5. Donát, J.: Hormonální substituční terapie. Hradec Králové: DoMeNa, 1999.
6. Genazzani, A. R., et al.: Controversial issues in climacteric medicine: cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop 2000, Royal Society of Medicine, London. Maturitas, 2001, vol. 38, p. 263-271.
7. Gregor, P., et al.: Kardiologie. 2. vyd. Praha: Galén, 1999, s. 168-169.
8. Grodstein, F., Stampfer, M., Manson, J. E., et al.: Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med., 1996, vol. 335, p. 453-461.
9. Hejdová, M., Vlček, J., Kučera, Z.: Spotřeba estrogenové substitučni terapie v okrese Hradec Králové, Gynekolog, 2003, vol. 12, č. 2, s. 77-80.
10. Hodis, H. N., Mack, W. J., Azen, S. P., et al. for the Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med., 2003, vol. 349, p. 535-545.
11. Konštacký, M.: Možný podíl infekce Helicobacter pylori v etiopatogenezi ischemické choroby srdeční, Disertační práce, UK v Praze, Lékařská fakulta v Hradci Králové, 2003, s. 64.
12. Masopust, J.: Klinická biochemie. 1. vyd., Praha: Karolinum, 1998, s. 491-494.
13. McCully, K. S., Wilson, R. B.: Homocysteine theory of arteriosclerosis. Atherosclerosis, 1975, vol. 22, p. 215-227.
14. Hijatovic, Y., Kenemans, P., Jakobs, C., et al.: A randomized controlled study of the effects of 17β□-estradiol - dydrogesterone on plasma homocysteine in postmenopausal women. Obstet. Gynecol., 1998, vol. 91, p. 432-436.
15. Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 2003, vol. 362, p. 419-427.
16. Nanda, S., Gupta, N., Mehta, H. C., Sangwan, K.: Effect of oestrogen replacement therapy on serum lipid profile. Aust. N. Z. J. Obstet. Gynaecol., 2003, vol. 43, 3, p. 213-216.
17. Ott, A., Breteler, M. M. B., Van Harskamp, F., et al.: Prevalence of Alzheimer's disease and vascular dementia, association with education. The Rotterdam study. Br. Med. J., 1995, vol. 310, p. 970-973.
18. Rapp, S. R., Espeland, M. A., Shumaker, S. A., et al.: Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal Women: The Women's Health Initiative Memory study, a randomised controlled trial. JAMA, 2003, vol. 289, 20, p. 2663-2672.
19. Ridker, P. M., Stampfer, M. J., Rifai, N.: Netradiční rizikové faktory systémové aterosklerózy. JAMA - CS, 2001, vol. 10, Kardiologie, s. 750.
20. Rifai, N., Ridker, P. M.: High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chemistry, 2001, vol. 47, 3, p. 403-411.
21. Rushakoff, R., Kalkhoff, R.: Effects of pregnancy and sex steroid administration on skeletal muscle metabolism in the rat. Diabetes, 1981, vol. 30, p. 545-550.
22. Sfoarotini, E., Kyriakides, Z. S., Kremastinos, B. T.: Effect of simvastatin on serum C-reactive protein during hormone replacement therapy. Am. J. Cardiol., 2004, vol. 15, 2. p. 217-218.
23. Shumaker, S. A., Legault, C., Thai, L., et al.: WHIMS Investigators: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory study: a randomised controlled trial. JAMA, 2003, vol. 289, 20, p. 2651-2662.
24. Šormová, I.: Diskuse nad studií "Million Women Study", Klimakter. Med., 2003, vol. 8, č. 4, s. 13-16.
25. The North American Menopause Society issues initial reaction to termination of estrogen-only arm of the women's health initiative. Cleveland, 2004, 3.
26. Walsh, B. W., Paul, S., Wild, R. A., et al.: The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocystein in healthy post-menopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab., 2000, vol. 85, p. 214-228.
27. Writing Group for the Women's Health Iniciative: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Iniciative randomized controlled trial. JAMA, 2002, 288, 3, p. 321-333.